Back to Report Store Home

Pancreatic Cancer Therapeutics in Major Developed Markets to 2021 - Strong Late Stage Pipeline Holds Promise for Increasingly Diverse Market Landscape

  • Published: Dec-2015
  • Report Code: GBIHC377MR
  • Report Format: pdf

Description

Table of Contents

1 Table of Contents 6

1.1 List of Tables 8

1.2 List of Figures 9

2 Introduction 11

2.1 Disease Introduction 11

2.2 Epidemiology 11

2.3 Symptoms 12

2.4 Risk Factors 13

2.4.1 Age 13

2.4.2 Smoking 13

2.4.3 Obesity 13

2.4.4 Diet 13

2.4.5 Inherited Mutations 14

2.4.6 Chronic Pancreatitis 14

2.4.7 Diabetes 14

2.4.8 Infectious Diseases Risk Factors 14

2.4.9 Precursor Lesions 15

2.5 Pathophysiology 15

2.5.1 Somatic Mutations 15

2.6 Disease Stages 17

2.7 Diagnosis 18

2.8 Disease Prognosis 19

2.9 Treatment Algorithm 19

2.9.1 Adjuvant Therapy, Resected Cancer 20

2.9.2 First-Line Treatment, Unresectable 21

2.9.3 Second-Line Treatment, Unresectable 22

3 Commercial and Clinical Prospects of Marketed Products 24

3.1 Approved Products 24

3.1.1 Gemcitabine 24

3.1.2 IV Fluorouracil 25

3.1.3 Abraxane 26

3.1.4 Tarceva 27

3.1.5 Teysuno/TS-1/S-1 28

3.1.6 Onivyde 29

3.2 Off-Label Products 30

3.2.1 Capecitabine 30

3.2.2 Oxaliplatin 31

3.3 Marketed Products – Discussion 31

4 Pipeline for Pancreatic Cancer Therapeutics 36

4.1 Overview by Phase and Molecule Type 37

4.2 Overview by Molecular Target 38

4.3 Clinical Trials 42

4.3.1 Clinical Trial Failure Rates 42

4.3.2 Clinical Trial Duration 46

4.3.3 Clinical Trial Size 50

4.3.4 Discussion 55

4.4 Promising Pipeline Molecules 55

4.4.1 Evofosfamide (TH-302) - Threshold Pharmaceuticals. 55

4.4.2 Tertomotide – Kael-GemVax 58

4.4.3 Ruxolitinib phosphate – Incyte Corporation 59

4.4.4 HyperAcute Pancreas/ Algenpantucel-L – NewLink Genetics Corporation 62

4.4.5 G17DT – Cancer Advances 64

4.4.6 Nimotuzumab – InnoMab 65

4.4.7 Clivatuzumab Tetraxetan – Immunomedics. 66

4.5 Pipeline Discussion 68

5 Market Forecast to 2021 72

5.1 Global Market 73

5.2 North America 74

5.2.1 US 74

5.2.2 Canada 77

5.3 Top Five European Markets 79

5.3.1 Treatment Usage Patterns 79

5.3.2 Annual Cost of Treatment 81

5.3.3 Market Size 82

5.3.4 Japan 84

6 Drivers and Barriers 87

6.1 Drivers 87

6.1.1 Rising prevalence across all target markets 87

6.1.2 Orphan Indication Incentives 87

6.1.3 Growing Disease Awareness 88

6.1.4 Better Diagnostics 88

6.1.5 All Treatment Segments Have an Unmet Need 88

6.1.6 High Number of Candidates in Late-Stage Drug Development 88

6.2 Barriers 89

6.2.1 Generics Will Restrict Premium Pricing 89

6.2.2 High Failure Rates 89

6.2.3 The High Genetic Heterogeneity of PC 89

6.2.4 Typical Late Stage of Diagnosis 89

7 Strategic Consolidations 91

7.1 Major Co-Development Deals 91

7.1.1 Merck Serono Enters into Co-development Agreement with Threshold Pharma for TH-302 93

7.1.2 GSK Enters into Co-development Agreement with OncoMed Pharmaceuticals for Novel Antibody Therapeutics 94

7.1.3 OncoMed Pharma Enters into Co-development Agreement with Celgene Corporation for Anti-Cancer Stem Cell Therapies 94

7.2 Major Licensing Deals 95

7.2.1 Baxter International Enters into a Licensing Agreement with Onconova Therapeutics for Rigosertib 97

7.2.2 Janssen Biotech Enters into Worldwide Licensing Agreement with Pharmacyclics for PCI-32765 98

7.2.3 AVEO Pharmaceuticals Enters into a License and Development Agreement with Schering-Plough Corporation for AV-299 98

7.2.4 Ardea Biosciences Enters Into a Licensing Agreement with Bayer HealthCare to Develop MEK Inhibitors 99

8 Appendix 100

8.1 All Pipeline Drugs by Phase 100

8.1.1 Discovery 100

8.1.2 Preclinical 103

8.1.3 Phase I 106

8.1.4 Phase II 109

8.1.5 Phase III 113

8.1.6 Pre-Registration 114

8.2 Market Forecasts to 2020 114

8.2.1 Global 114

8.2.2 The US 115

8.2.3 Canada 115

8.2.4 The UK 116

8.2.5 France 116

8.2.6 Germany 116

8.2.7 Italy 117

8.2.8 Spain 117

8.2.9 Japan 117

8.3 References 118

8.4 Abbreviations 132

8.5 Methodology 134

8.6 Coverage 134

8.7 Secondary Research 135

8.8 Therapeutic Landscape 135

8.9 Epidemiology-Based Forecasting 135

8.9.1 Analogous Forecasting Methodology 136

8.10 Market Size by Geography 136

8.10.1 Forecasting Model for Therapeutic Areas 137

8.11 Geographical Landscape 137

8.12 Pipeline Analysis 137

8.13 Competitive Landscape 138

8.14 Contact Us 138

8.15 Disclaimer 138

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards